Cell line · CVCL_1622
Papers42
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| A First-in-Class LZK Inhibitor Suppresses Tumor Growth and Potentiates EGFR and PI3K Pathway Blockade in Head and Neck and Esophageal Cancers. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Alcohol exposure promotes cell communication network 1 cleavage in esophageal adenocarcinoma cells exclusively. | J Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Suppression of AKT Activation through LZK Inhibition Limits Tumor Growth in Esophageal and Head and Neck Cancers. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi-omic integration identifies broad drug resistance mechanisms and strategies to therapeutically reprogram cancer cells. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MicroRNA 196a contributes to the aggressiveness of esophageal adenocarcinoma through the MYC/TERT/NFκB axis. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release. | J Immunother Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. | Sci Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Retroelement co-option disrupts the cancer transcriptional programme. | Genome Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The pluripotency factor NANOG contributes to mesenchymal plasticity and is predictive for outcome in esophageal adenocarcinoma. | Commun Med (Lond) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair. | Clin Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Probiotic-derived ferrichrome induces DDIT3-mediated antitumor effects in esophageal cancer cells. | Heliyon | 2024 | Its Methods give the RRID and name the line | PubMed | |
| miRNA-221 and miRNA-483-3p Dysregulation in Esophageal Adenocarcinoma. | Cancers (Basel) | 2024 | Its Methods give the RRID and name the line | PubMed | |
| NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route. | Cancer Cell Int | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 38234835 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| The transcriptional landscape of endogenous retroelements delineates esophageal adenocarcinoma subtypes. | NAR Cancer | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. | Cell Rep Med | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1622/papers